-
Electronic (PDF)
-
Site License
-
Enterprisewide
Human Papillomavirus Infection - Pipeline Review, Q1 2011
Global Markets Direct, March 2011, Pages: 51
Human Papillomavirus Infection - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Human Papillomavirus Infection - Pipeline Review, Q1 2011', provides an overview of the Human Papillomavirus Infection therapeutic pipeline. This report provides information on the therapeutic development for Human Papillomavirus Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infection. 'Human Papillomavirus Infection - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Human Papillomavirus Infection.
- A review of the Human Papillomavirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Human Papillomavirus Infection pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infection.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infection pipeline depth and focus of Human Papillomavirus Infection therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Human Papillomavirus Infection Overview
Therapeutics Development
An Overview of Pipeline Products for Human Papillomavirus Infection
Human Papillomavirus Infection Therapeutics under Development by Companies
Human Papillomavirus Infection Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Human Papillomavirus Infection Therapeutics - Products under Development by Companies
Human Papillomavirus Infection Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Human Papillomavirus Infection Therapeutics Development
F. Hoffmann-La Roche Ltd.
Helix BioPharma Corp.
GlaxoSmithKline plc
Merck & Co., Inc.
Crucell N.V.
Bio-Bridge Science, Inc.
Starpharma Holdings Limited
BioMAS Ltd.
ApoImmune, Inc.
PDS Biotechnology Corporation
Lumavita AG
ImmunoVaccine Technologies Inc.
BT PHARMA
iBio, Inc.
Genetic Immunity, LLC
IRX Therapeutics, Inc.
Human Papillomavirus Infection - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
V503 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cervarix + Boostrix + Menactra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cervarix + Boostrix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Human Papillomavirus Quadrivalent Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Propranolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Papillomavirus Infection Therapeutics - Discontinued Products
Human Papillomavirus Infection - Featured News
Oct 19, 2010: Helix BioPharma Files IND For Planned Phase II/III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Cervical Lesions
Jul 23, 2010: Genticel Receives Approval To Begin Phase I Clinical Trial Of ProCervix In Belgium
Jun 23, 2010: Helix BioPharma Corp. Announces Positive Phase II Pharmacokinetic Findings for Topical Interferon Alpha-2b in Patients With Low-Grade Cervical Lesions
Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
Mar 22, 2010: Helix BioPharma Corp Achieves Last-Patient-Out In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts
Feb 12, 2010: Helix BioPharma Announces Positive Interim Results From Its Ongoing Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients With Low-Grade Cervical Lesions
Nov 05, 2009: Helix BioPharma Corp Completes Enrollment In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts
Oct 06, 2009: Helix BioPharma Provides Updates On Topical Interferon Alpha-2b Following Pre-IND Meetings With The U.S. FDA
Oct 01, 2008: ImmunoVaccine Technologies’ DepoVax Shows Positive Results for Cancer and Infectious Diseases
Sep 22, 2008: Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Human Papillomavirus, Q1 2011
Products under Development for Human Papillomavirus – Comparative Analysis, Q1 2011
Comparative Analysis by Late Stage Development, Q1 2011
Comparative Analysis by Mid Clinical Stage Development, Q1 2011
Comparative Analysis by Early Clinical Stage Development, Q1 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q1 2011
F. Hoffmann-La Roche Ltd., 2011
Helix BioPharma Corp., 2011
GlaxoSmithKline plc, 2011
Merck & Co., Inc., 2011
Crucell N.V., 2011
Bio-Bridge Science, Inc., 2011
Starpharma Holdings Limited, 2011
BioMAS Ltd., 2011
ApoImmune, Inc., 2011
PDS Biotechnology Corporation, 2011
Lumavita AG, 2011
ImmunoVaccine Technologies Inc., 2011
BT PHARMA, 2011
iBio, Inc., 2011
Genetic Immunity, LLC, 2011
IRX Therapeutics, Inc., 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Discontinued Products
List of Figures
Number of Products under Development for Human Papillomavirus, Q1 2011
Products under Development for Human Papillomavirus – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Late Stage Products, Q1 2011
Mid Clinical Stage Products, Q1 2011
Early Clinical Stage Products, Q1 2011
Discovery and Pre-Clinical Stage Products, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
